Brief: Lineage Cell Therapeutics Presents Additional Interim Data On OpRegen

Lineage Cell Therapeutics

23/03/2021 12:23

March 23 (Reuters) - Lineage Cell Therapeutics Inc  LCTX.A :
    * LINEAGE CELL - ANNOUNCED NEW POSITIVE INTERIM RESULTS FROM
ONGOING, 24-PATIENT PHASE 1/2A CLINICAL STUDY OF LEAD PRODUCT
CANDIDATE, OPREGEN
    * LINEAGE CELL THERAPEUTICS INC - SEVENTY-FIVE PERCENT OF
ALL
COHORT 4 PATIENTS HAVE EXPERIENCED BCVA INCREASES
    * LINEAGE CELL - NO ACUTE OR DELAYED INFLAMMATION OR
REJECTION OF
OPREGEN OBSERVED, EVEN IN PATIENTS TREATED WITH REDUCED
IMMUNOSUPPRESSIVE REGIMEN
    * LINEAGE CELL THERAPEUTICS INC - OVERALL, OPREGEN HAS BEEN
WELL
TOLERATED WITH NO UNEXPECTED ADVERSE EVENTS OR SERIOUS ADVERSE
EVENTS

Source text for Eikon:  ID:nBw3hzdYwa 
Further company coverage:  LCTX.A 

 ((Reuters.Briefs@thomsonreuters.com;))